Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, Wadleigh M, Cortes J, Thompson J, Guhl J, Horowitz MM, Flynn KE.
Atallah E, et al. Among authors: flynn ke.
BMC Cancer. 2018 Apr 2;18(1):359. doi: 10.1186/s12885-018-4273-1.
BMC Cancer. 2018.
PMID: 29609532
Free PMC article.